Please use this identifier to cite or link to this item:
|Title:||Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat.|
|Authors:||Burrell, Louise M;Phillips, P A;Risvanis, John;Chan, Robert K;Aldred, K L;Johnston, Colin I|
|Affiliation:||Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Heidelberg 3084, Victoria, Australia.|
|Citation:||The American Journal of Physiology; 275(1 Pt 2): H176-82|
|Abstract:||The hormone arginine vasopressin (AVP) contributes to water retention and vasoconstriction in congestive heart failure (CHF) through effects at the V2 and V1a receptors, respectively. The effect of long-term V2 receptor (V2R) blockade using OPC-31260 was assessed in a rat model of postinfarction-induced CHF. Rats underwent coronary artery ligation or sham operation and were treated for 6 mo with oral OPC-31260 (10 mg . kg-1 . day-1) or vehicle. CHF was characterized by left ventricular remodeling and impaired systolic function, increased cardiac and lung weight, and elevated plasma atrial natriuretic peptide; plasma AVP and plasma renin activity were not increased. Chronic V2R blockade increased urine volume (P < 0.01) and decreased urine osmolality (P < 0.01) but had no natriuretic effects. V2R blockade did not activate the renin-angiotensin system but increased plasma AVP in CHF (P < 0.01). V2R blockade did not influence cardiac remodeling, cardiac function, or survival. These results suggest that AVP plays a major role in water retention through the renal V2R in a rat model of CHF. V2R blockade using OPC-31260 may represent an alternative to standard diuretic therapy in the management of water retention that characterizes heart failure.|
|Internal ID Number:||9688911|
Antidiuretic Hormone Receptor Antagonists
Blood Pressure.drug effects
Body Weight.drug effects
Organ Size.drug effects
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.